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Co-carcinogenic effects of vitamin E 
in prostate
fabio Vivarelli1, Donatella Canistro  1, Silvia Cirillo1, Alessio papi2, enzo Spisni2, 
Andrea Vornoli3, Clara M. Della croce4, Vincenzo Longo4, Paola franchi5, Sandra Filippi6, 
Marco Lucarini5, Cristina Zanzi7, Francesca Rotondo8, Antonello Lorenzini  9, 
Silvia Marchionni  9 & Moreno Paolini1
A large number of basic researches and observational studies suggested the cancer preventive activity 
of vitamin E, but large-scale human intervention trials have yielded disappointing results and actually 
showed a higher incidence of prostate cancer although the mechanisms underlying the increased risk 
remain largely unknown. Here we show through in vitro and in vivo studies that vitamin E produces a 
marked inductive effect on carcinogen-bioactivating enzymes and a pro-oxidant status promoting both 
DNA damage and cell transformation frequency. First, we found that vitamin E in the human prostate 
epithelial RWPE-1 cell line has the remarkable ability to upregulate the expression of various phase-I 
activating cytochrome P450 (CYP) enzymes, including activators of polycyclic aromatic hydrocarbons 
(PAHs), giving rise to supraphysiological levels of reactive oxygen species. Furthermore, our rat model 
confirmed that vitamin E in the prostate has a powerful booster effect on CYP enzymes associated with 
the generation of oxidative stress, thereby favoring lipid-derived electrophile spread that covalently 
modifies proteins. We show that vitamin E not only causes DNA damage but also promotes cell 
transformation frequency induced by the PAH-prototype benzo[a]pyrene. Our findings might explain 
why dietary supplementation with vitamin E increases the prostate cancer risk among healthy men.
Prostate cancer is the most common human malignancy and the second leading cause of cancer death among 
men in western nations. The high global incidence of prostate cancer, the unsatisfactory outcomes of surgery 
and radiotherapy and the cost of curative therapies have led to a focus on primary prevention as a major public 
health goal1,2. Supported by preclinical and epidemiological evidence, antioxidants from food and supplements 
are widely used to protect against cancer, but clinical trials do not sustain this concept1,3–6 and actually showed 
a higher incidence of prostate cancer7,8. Conceived to break through this issue, in 2001 the National Cancer 
Institute (NCI) launched SELECT (Selenium and vitamin E Cancer Prevention Trial), that showed a 17% increase 
in prostate cancer incidence in the vitamin E arm compared to placebo7.
A growth-promoting effect of vitamin E on organoids has recently been reported9, but its mechanism of action 
remains poorly understood. Since some cytochrome P-450 (CYP) isoforms have been found overexpressed in 
prostate cancer10–15, we suspected that vitamin E could have co-carcinogenic properties such as those involving 
carcinogen-bioactivating CYP-enzyme changes16,17.
Results and Discussion
Our study stemmed from the observation that vitamin E treatment of the human non-tumorigenic prostate 
epithelial RWPE-1 cell line induces the gene expression of P450 enzymes such as CYP1A1 (activating, for exam-
ple, polychlorinated biphenyls, aromatic amines, PHAs and alkylnitrosamines), CYP1A4 (activating polycyclic 
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aromatic hydrocarbons, PAHs), CYP4F2 (the major enzyme involved in vitamin E metabolism), CYP2C9 (acti-
vating heterocyclic aromatic amines and PAHs), and an up to 18-fold increase in the expression of CYP2B6 
(activating tobacco smoke pro-carcinogens such as 4-methylnitrosamino-1-3-pyridyl-1-butanone, NNK) 
(Fig. 1a). These results suggested that vitamin E enhances the bioactivating potential of the CYP supergene 
family, making prostate cells more vulnerable to exposure to pro-mutagenic and pro-carcinogenic agents. It is 
noteworthy that a meta-analysis revealed that CYP1A1 polymorphisms are closely related to the prostate cancer 
risk11, and that CYP1A1 and CYP1B1 are overexpressed in prostate cancer cells10–13. Conversely, reduced basal 
CYP1A1 mRNA expression leads to an inhibition of cell proliferation by inducing apoptosis in prostate cancer 
cells12. These data support the hypothesis that vitamin E could contribute to prostate carcinogenesis via CYP 
mediated mechanism.
We then used electron paramagnetic resonance (EPR) to evaluate the exact contribution of vitamin E-induced 
CYPs to superoxide radical production, finding that vitamin E in RWPE-1 prostate cells stimulates the produc-
tion of supraphysiological levels of reactive oxygen species (ROS) (Fig. 1b,c) primarily derived by uncoupling the 
CYP-Fe II-O2 complex of the CYP catalytic cycle18,19. These data provide evidence of the dual nature of vitamin 
E, a two-edged sword acting directly as an antioxidant and indirectly as a pro-oxidant20. In addition, vitamin 
E plays a critical role in impairing redox homeostasis, while the pro-inflammatory cyclooxygenase-2 (COX-2) 
prostaglandin-2 (PGE2) pathway is involved in various malignancies, including prostate cancer21,22, by means of 
resistance to apoptosis, increased proliferation, invasiveness, metastasis and angiogenesis. These findings are cur-
rently fuelling research focused on COX-2 inhibitors as an anti-cancer strategy23,24, so we performed experiments 
to detect these markers. We observed that vitamin E enhances the expression of COX-2 mRNA which, in turn, 
yields overproduction of its major metabolite PGE2 (Fig. 1d,e). These data reinforce the hypothesis of vitamin 
E’s role in growth-promoting prostate tumours, although, it should be taken into account that the concentration 
here tested is supraphysiological and higher compared to the circulating levels achieved in subjects enrolled in 
the SELECT study25.
To extend our analyses, we used a rat model to investigate whether vitamin E induces CYP expression and 
ROS generation in vivo. We observed that vitamin E treatment leads to increase in CYP1A1 gene expression in 
the prostate at all doses and timeframes considered, whereas CYP1A2 (activating dioxins, aromatic/heterocy-
clic amines, aflatoxins) and CYP1B1 (activating PAH, steroids) show a non-linear pathway of gene expression 
(Fig. 2a–c), the highest dose is associated to the more marked changes, whereas the low dosage shows a null effect 
after fourteen days (Fig. 2b,c) as well as a down-regulation in CYP1A2 at day seven (Fig. 2b). The correspond-
ing enzyme activities here considered result boosted across all groups (Fig. 2d). These apparent inconsistencies 
could be explained considering the complexity of the CYP450 modulation phenomenon that can occur following 
different pathways involving numerous nuclear receptors as well as different dose-depending or time-depending 
mechanisms that can lead to a post-translational process increasing protein stability as well as transcriptional 
induction26,27. Moreover, a dose-response/time-response hormesis could be also considered as a putative expla-
nation for our results28.
We hypothesize that corresponding high levels of CYPs predispose a subject to prostate cancer risk from the 
ubiquitous widely bioactivated pro-carcinogens29,30.
Furthermore, using the EPR spin-trapping technique, we observed that vitamin E in rat prostate generates 
high ROS levels irrespective of doses or timing (Fig. 2e) along with typical markers of oxidative stress injuries 
such as lipid peroxidation (Fig. 2f) and protein carbonylation (Fig. 2g). Even if not all vitamin E-exposed groups 
tested positive, it should be considered that malondialdehyde (MDA) as a marker of lipid peroxidation and the 
protein carbonyls here reported, were carried out in the microsomal and cytosolic fractions, respectively, and it 
is plausible to assume that different subcellular fractions could differently react to ROS injuries. Furthermore, the 
inducible antioxidant enzymatic machinery might have had a role in counteracting the oxidative stress in specific 
cellular compartments. However, the reactive oxygen species yield determined by EPR in biopsy gives a complete 
and accurate picture of ROS content in the cellular and extracellular matrix (Fig. 2e). As a whole these results 
support the hypothesis of ROS over generation by CYP induction in prostate tissue that can result in cell damage 
and inflammation29. Although our result on oxidative stress markers did not show a linear trend, in their entirety, 
they are consistent with those emerged from the trial by Pearson and colleagues in which an increment of plasma 
oxidation activity levels was observed in patients receiving vitamin E31.
Collectively, our data strengthen the hypothesis that vitamin E could act as a co-carcinogenic agent by means 
of both its increased metabolic activating potential towards pro-mutagens/pro-carcinogens and its pro-oxidant 
activity and thus might drive tumorigenesis through DNA insults and epigenetic alterations. To test our hypoth-
esis, we examined whether vitamin E induces DNA damage to histone variant H2AX and 53BP1 as an indirect 
measure of double strand DNA breaks (DSBs)32. Although ROS pronominally lead to a single strand DNA breaks, 
DSBs can result following replication past oxidative stress-induced lesions33. We observed the appearance of a 
small proportion of human fibroblasts displaying more than 20 foci per nucleus in vitamin E-treated cultures 
(Supplementary Fig. S1). Although differences did not reach statistical significance, they suggest that vitamin E 
may impair genomic stability. Thus we measured micronuclei (MN) abundance after vitamin E pre-incubation, 
finding that vitamin E worsens the genomic stability of cells by significantly increasing the number of MN and 
also slightly increasing the number of MN in neocarzinostatin (NCS)-treated positive control cultures (Fig. 3a,b). 
It is reasonable to suppose that the CYP induced during the pre-incubation of fibroblasts with vitamin E are 
responsible for the subsequent ROS generation leading to DNA damage occurring without vitamin E being pres-
ent in the cultures. Indeed, cell incubation with DMSO, which has radical scavenging properties34, tends to restore 
the control level of MN, suggesting the possible oxidative nature of the damage (Fig. 3a).
Lastly, to test the co-carcinogenic properties of vitamin E directly, we used the BALB/c 3T3 in vitro cell trans-
formation assay (CTA), which models key stages of in vivo carcinogenesis and has been proposed as an alterna-
tive to the rodent cancer bioassay35. Cells were pre-incubated with vitamin E, then treated with the ubiquitous 
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environmental pollutant carcinogenic benzo[a]pyrene (B[a]P) selected as a PAH prototype. Vitamin E signifi-
cantly enhanced the cell transformation frequency (TF) of B[a]P-transformed cells, whereas it did not induce cell 
transformation per se or prevent B[a]P-induced transformation (Fig. 3b).
Figure 1. Vitamin E in RWPE-1 cell line induces CYP gene expression coupled with increased ROS release 
and inflammation markers. (a) Gene expression study on RWPE-1 cells revealed sharp increments in mRNA 
levels from vitamin E-exposed cells compared to control. CYP1A1 and CYP1A4 are doubled (P < 0.05; 
n = 3). Isoforms 2B6, 2C9 and 4F2 showed the most pronounced changes with 18, 4 and 7 fold-higher levels 
respectively (P < 0.05; n = 3). (b) Free radical measurements through EPR spectroscopy in RWPE-1 cell line. 
The scattered dot plot represents total oxygen, nitrogen, and carbon-centered free radical species (arbitrary 
units) measured in RWPE-1 cells 48 hours after vitamin E exposure. Exposed cells (n = 5) exhibited significantly 
higher levels of radical species compared to controls (n = 4; P < 0.05). (c) Representative EPR spectra of 
nitroxide radicals observed in RWPE-1 control samples (green spectra), and in vitamin E-exposed samples 
(red spectra). EPR intensity of the first spectral line was used to obtain the relative amount of nitroxide in each 
sample examined. (d) Vitamin E-exposed cells (100 μM; 48 h) exhibited higher COX-2 mRNA levels (P < 0.05; 
n = 3). (e) COX-2 mRNA induction was coupled with an increased PGE2 secretion (P < 0.01; n = 3). Each bar 
represents the mean (±SD) P < 0.05, **P < 0.01 two-tailed t-test. (Control vs groups of each treatment).
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Figure 2. Vitamin E in rat prostate boosts CYP gene expression and linked enzymatic activities, and impairs 
the redox imbalance. (a) Data from RT-PCR analysis reported a marked increment of CYP1A1 throughout 
treatment (P < 0.001; n = 5). (b) CYP1A2 presented a non-linear pathway of modulation with a significant 
inhibition at the lowest dose (7 days) that was not confirmed after 14 days. 200 mg/kg b.w. led to a net 
upregulation at both time windows. (c) CYP1B1 showed a trend similar to that described for CYP1A1 although 
changes were milder. 100 mg/kg b.w. treatment showed a 32% (P < 0.001; n = 5) increment after 7 days that 
became non-significant at the fourteenth day. The highest dose resulted in 74 and 46% increments after 7 and 
14 days, respectively (P < 0.001; n = 5). (d) CYP1A1/2-ethoxyresorufin O-deethylase increased from 26% 
at the lowest dosage for 7 days to more than 100% after 14 days of treatment. The highest dose more than 
doubled at both time windows. CYP2B1/2-pentoxyresorufin O-dealkylase rose from 26 to 124% (P < 0.01; 
n = 6), depending on the dose when vitamin E was administered for 7 days, whereas changes became less 
marked (about 85% and 50%) after 14 days(P < 0.0; n = 6). (e) EPR in prostate tissue biopsies from vitamin 
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These results are consistent with the observed inducing effect of vitamin E toward the CYP1A1 isoform, the 
main enzyme responsible for (B[a]P) activation. It can be argued that by boosting phase-I CYP bioactivating 
enzymes during cell growth, vitamin E may then trigger the conversion of (B[a]P) to ultimate more carcinogenic 
reactive intermediates such as diol-epoxides12.
In summary, this work demonstrates that vitamin E has a co-carcinogenic effect by boosting the enzymes that 
bioactivate the pro-carcinogens usually found up regulated in prostate tumours and advocated as promising tar-
gets for cancer treatment12,13. Our results are in line with those previously reported by McCormick and colleagues 
who found an increase in prostate cancer incidence in rats fed 4000 mg/kg vitamin E in the diet36. However, it 
is mandatory to point out that cell lines were exposed to approximately 2.5 fold higher vitamin E concentration 
compared to the amount (16 µg/mL) reached in the study by McCormick et al., as well as 100 and 200 mg/kg b.w. 
i.p. (16,5–33 mg/rat weighing 165 g) would result in a vastly higher circulating vitamin E levels compared to the 
rat feeding study quoted above36 and to patients from SELECT (<9–~20 μg/mL)25. Furthermore, we demon-
strated that vitamin E generates a persistent oxidative stress, which in turn leads to a flare-up in inflammation 
recently associated with the prostate cancer risk in a prospective study combining data from the Prostate Cancer 
Prevention Trial (PCPT) and the SELECT cohorts37. On the other hand, oxidative stress is widely involved in the 
initiation and development of many malignancies, including prostate cancer38.
Conclusions
Consistent with these mechanisms, our study also demonstrated that vitamin E promotes DNA damage and cell 
transformation, thereby providing a biological rationale for the paradoxical effect of the increased prostate cancer 
incidence among healthy men supplemented with vitamin E in the SELECT study7, even if we have to bear in 
mind that results here discussed were achieved exposing cell lines and animals to higher vitamin E concentrations 
compared to those reported in the SELECT. Other factors contributing to prostate cancer development by vitamin 
E cannot be excluded. Our study adds new evidence that some antioxidants exert a dichotomous suppressive and 
promoting activity with respect to tumorigenesis39.
The present work should not be intended as a translational study. The models here discussed had the only 
purpose to test the hypothesis of a co-carcinogenesis mechanism of vitamin E through CYP supergene family 
induction. The dosages here used are not referred to human consumption of vitamin E neither to those described 
in the SELECT; such a limitations should be considered.
Methods
Chemicals. The form of vitamin E considered in the study was DL-all-rac α-tocopherol (PubChem CID: 
2116) purchased from Sigma Aldrich Chemicals Co (USA). Neocarzinostatin (NCS) was also from Sigma Aldrich 
Chemicals.
Cell culture and exposure. The prostate epithelial cell line RWPE-1 (normal prostatic epithelial cells 
derived from histological normal adult prostate) was obtained from Dr. Catia Giovannini, Center for Applied 
Biomedical Research, St. Orsola-Malpighi University Hospital, Bologna, Italy. RWPE-1 was used and cultured 
in a standard 37 °C humidified incubator with 5% carbon dioxide and 95% oxygen. RWPE-1 was cultured in 
defined keratinocyte serum-free medium (KSFM) supplemented with human recombinant epidermal growth 
factor (rEGF) and bovine pituitary extract (BPE) (Gibco, USA). Cells were plated at a density of 5 × 105 cells/
well in 6-well plates and cultured until they reached a 50–60% confluence and then treated with vitamin E 
((+)-α-tocopherol, C29H5O2) solubilized in dimethyl sulfoxide (DMSO) 0.1%. Vitamin E concentrations used 
for cell treatments ranged from 25 μM (comparable to physiological plasma levels) to 150 μM40,41, DMSO was 
also added in untreated control cells.
Cell viability. Cell viability was measured by Sulphorodamine B assay (SRB assay, Sigma, USA) in according 
to the manufacture’s sheet. The absorbance was read at 570 nm. Vitamin E did not show cytotoxic activity against 
the RWPE-1 cell line, even at high doses, after 72 hours (data not shown).
RNA extraction from RWPE-1 cells and gene expression analysis. Total RNA from vitamin 
E-treated (100 μM; 48 h) RWPE-1 cells was extracted using Trizol reagent (Life Technologies, CA, USA) in 
accordance to the manufacturer’s instructions. DNase I treatment (DNA-free kit, Ambion, USA) was adopted 
to remove any genomic DNA contamination. Extracted RNA samples were reverse-transcripted using using 
RevertAid™ First Strand cDNA Synthesis Kits (Fisher Scientific, KS, USA)42. CYPs, COX-2 and β-actin mRNA 
levels were analyzed by real-time PCR using SYBR- Select Master Mix (Life Technologies, CA, USA) and StepOne 
PlusTM system (Applied Biosystems, CA, USA). The melting curve data were collected to check PCR specific-
ity. Each cDNA sample was analyzed in triplicate. Target mRNA levels were normalized against β-actin mRNA 
Relative expressions were calculated using the formula 2−2ΔCt values (ΔCt = Ctgene − Cthk). Primers were 
E-injected rats (both doses and time frames) reported significantly (P < 0.05; n = 5) higher levels of radical 
species compared to controls. (f) Data from TBARS assay plot indicated a general trend toward oxidative 
stress in prostate tissue of vitamin E-treated animals, even if only the 14-day treatment (both doses) reached 
statistical significance (P < 0.05; n = 6). (g) Carbonylated proteins showed a sharp increment when vitamin E 
was administered for 7 days (P < 0.01; n = 9), whereas, extending the treatment to 14 days led to an almost full 
recovery. Bars represent the mean (±SD). All data were analyzed by the ANOVA test corrected for multiple 
comparisons (Sidak post-hoc). *P < 0.05; **P < 0.01; ***P < 0.001 (Control vs groups of each treatment).
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purchased from IDT technologies (USA). All samples containing 200 ng of cDNA were run in triplicate. The ther-
mal cycler was programmed as follows: 30 s at 95 °C and 40 cycles of 5 s at 95 °C and 20 s at 60 °C for amplification.
Primer sequences:
β-actin: F5′-GGCGGCACCACCATGTACCCT-3′; R5′-AGGGGCCGGACTCGTCATACT-3′;
CYP1A1: F5′-CAAGAGGAGCTAGACACAGT-3′; R5′-AGCCTTTCAAACTTGTGTCT-3′;
CYP1A2: F5′-GGACAGCACTTCCCTGAGAG-3′; R5′GAGGCAGTCTCCACGAACTC-3′;
CYP3A5: F5′-GCTCGCAGCCCAGTCAATA-3′; R5′-AGGTGGTGCCTTATTGGGC-3′;
CYP1B1: F5′-TTCGGCCACTACTCGGAGC-3′; R5′-AAGAAGTTGCGCATCATGCT-3′;
CYP2B6: F5′-TCCAGTCTCAGCTCCCAAGT-3′; R5′-CTGGCCAACATGTCCCTACT-3′;
CYP2C9: F5′-CCACATGCCCTACACAGATG-3′; R5′-TGCCCTTGGGAATGAGATAG-3′;
CYP4F2: F5′-GACACCAGGGCATGGTCAACC-3′; R5′-CGGCAATATATTCACTGGGTTTC-3′;
COX-2: F5′-CCTGTGCCTGATGATTGC-3′; R5′-CTGATGCGTGAAGTGCTG-3′.
Electronic paramagnetic resonance (EPR) measurements. This method was previously employed as 
an accurate measure of total radical species in different tissues43. The biopsies are dissolved in a 1 mM solution of 
the hydroxylamine “spin trap” (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decandioate dihydrochloride 
Figure 3. Vitamin E promotes DNA damage and cell transformation. (a) Human fibroblasts (IMR90) were 
treated with vitamin E (100 µM) and/or neocarzinostatin (NCS, used as positive control), 0.1 µM or 0.5 µM. 
DMSO was applied in control samples since it was used to dilute vitamin E. After 48 h of pre-incubation 
with vitamin E the cells were treated with NCS for 2 h and finally with MEM for 24 h (see Table below the 
histogram). The micronuclei were scored counting at least 1,000 nuclei per sample. A significance difference 
was observed between control and vitamin E-treated samples (P < 0.05) and between control and NCS-treated 
samples (P < 0.01 and P < 0.001). Bars represent the mean (±SE). All data were analyzed by the unpaired 
t-test *P < 0.05; **P < 0.01; ***P < 0.001. (b) An example of DAPI-stained nuclei of cells pre-incubated with 
DMSO (control, upper) and DMSO plus vitamin E (below). Arrows indicate micronuclei. (c) BALB/c3T3 cells 
were seeded for cellular transformation assay (CTA), maintained in culture for 24 h and exposed to minimum 
essential medium (MEM) supplemented with 10% fetal bovine serum (MEMF), 0.1% DMSO or 100 µM vitamin 
E for 24 h. Then cells were treated with B[a]P (final concentrations 0.01 - 0.1 - 1 µg/ml) for 48 h. Four weeks after 
seeding, cells were fixed, stained and scored for transformed foci. The type III foci number was determined in 
each plate, according to the established scoring criteria. Statistical analysis of foci distribution was performed by 
the Mann–Whitney unpaired t-test. The transformation frequency (TF) was calculated on the basis of the foci 
number divided by the clonal efficiency (ACE) observed in the cytotoxicity assay performed concurrently. ACE 
represented the number of cells surviving chemical treatment. Cells treated with vitamin E and then with B[a]
P at concentrations leading to cell transformation showed a significant increase in TF (P < 0.01, Exact Poisson 
test). (Control vs groups of each treatment).
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CAS no. 314726-62-0) and incubated at 37 °C for 5 minutes. Samples from the solution are loaded in a capillary 
glass tube and inserted in the cavity of a Bruker ESP 300 EPR spectrometer (Bruker Biospin S.r.l., Rheinstetten, 
Germany). The nitoxide spectra were recorded at the following settings: modulation amplitude = 1.0 G; conver-
sion time = 163.84 ms; time constant = 163.84 ms; modulation frequency 100 kHz; microwave power = 6.4 mW. 
All specifications about instrument calibration and data elaboration were previously reported38. Tests on RWPE-1 
cells were carried out as the procedures described above: cells were seeded in a 6-well plate at a density of 7 × 105 
cells per well and collected in serum-free medium for 48 h with vitamin E or PBS. The medium was discarded 
and cells detached with a scraper. Cells were centrifuged at 300 × g for 5 min and suspended in 500 μL of PBS 
1X + 500 μL of hydroxylamine “spin trap” (bis(1-hydroxy-2,2,6,6-tetramethyl-4-piperidinyl) decandioate dihy-
drochloride (1 mM final concentration).
PGE2 measurement through ELISA tests. PGE2 in RWPE-1 supernatants was determined using the 
PGE2 ELISA assay (Cayman, Ann Arbour, USA). Briefly, cells were seeded in a 6-well plate at a density of 3 × 105 
cells per well in serum-free medium for 48 h in the presence or absence of vitamin E. The harvested media were 
centrifuged at 500 × g for 5 min (4 °C) to remove floating cells. Supernatants were finally assayed following the 
supplier’s instructions and the absorbance was measured by using a microplate reader (Bio-Rad, USA) at 570 nm.
Animal treatment. The study was approved by the University of Bologna Committee on the Ethics of 
Animal Experiments and by the Italian Ministry of Health (Prot n. 43 IX-9). All experiments were performed 
in accordance with relevant guidelines and regulations. 8 week-old male Sprague-Dawley rats weighing 150–
180 g were purchased from ENVIGO RMS S.r.l. (San Pietro al Natisone, Udine, Italy). They were housed under 
a 12h-light/12h-dark cycle, 22 °C, 60% humidity, and fed ad libitum with a standard rodent chow with a total 
amount of vitamin E around 123 mg/kg (Mucedola Srl). After an adequate period of acclimatization animals were 
randomly divided into 6 experimental units of 6 animals each. Vitamin E was dissolved in corn oil for fat-soluble 
compounds by Sigma-Aldrich Merck group and administered intraperitoneally (i.p.) at 100 or 200 mg/kg b.w. 
for 7 or 14 consecutive days. Controls received an equal volume of vehicle. The present work was not conceived 
as a translational study; therefore it does not intend to simulate a putative human intake. Dosages were based on 
literature review36,44,45.
Tissue collection and subcellular fractions. Animals were injected with Zoletil 100 (100 mg/kg b.w.) 
and then scarified according to the Ministerial procedures. The prostate was resected frozen in liquid nitrogen. 
Microsomes and cytosolic fraction were prepared as previously reported20.
mRNA extraction from prostate tissue and gene expression analysis. Total RNA was extracted 
from tissue by the use of the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) following the manufacturer’s sheet 
and then quantified using NanoDrop (Celbio). Purity and integrity levels were checked monitoring the absorb-
ance ratios A260/A280 nm and A260/230 and assessing the sharpness of 18S and 28S ribosomal RNA bands on 1% 
agarose gel stained with GelRed™ (Biotium, Hayward, CA). Genomic DNA elimination and reverse transcription 
of total RNA were performed using the QuantiTech Reverse Transcription Kit (Qiagen). Full details on procedure 
were previously reported46. β-actin was utilized as endogenous control to normalize for RNA loading or differ-
ences in reverse transcription efficiency.
Primer sequences:
CYP1A1: F5′-CTTGCAAAGCCCATGTTCCT-3′; R5′-TGGTGTAGCGGTTCATGACT-3′
CYP1A2: F5′-TGGTGGAATCGGTGGCTAAT-3′; R5′-TAAACCTCTTGAGGGCTGGG-3′
CYP1B1: F5′- GGTGGCTAATGTCATGAGCG-3′; R5′-AAGTTGCTGAAGTTGCGGTT-3′.
Data about gene expression discussed above were obtained through different RNA extraction methods. This 
represents a potential limitation of the study.
CYP1A1/2 and CYP2B1/2 enzyme activities. All enzymatic assays and protein concentrations were per-
formed as previously described47.
Lipid peroxidation and protein carbonylation. Protein carbonyl groups: the assay was performed in 
accordance with the method described by Levine and colleagues48 with slight changes. The carbonyl groups were 
determined following spectrophotometrically their covalent reaction with 2,4-dinitrophenylhydrazine (DNPH), 
that leads to the formation of a yellow 2,4-dinitrophenyl (DNP) hydrazone by-product. The cytosolic proteins 
were precipitated with cold trichloroacetic acid (TCA) 20% and then collected by 10 min centrifugation (4,000 g). 
A solution of 10 mM DNPH in 2 N HCl was added to the protein. Blanks were added with only 2 N HCl. Samples 
were incubated for 1 hour at room temperature vortexing every 10 min and then precipitated with TCA 20% and 
centrifuged. Pellets were washed three times with a solution of ethanol and ethyl acetate (1:1 v/v) and suspended 
in PBS buffer (pH 2,3). All samples were centrifuged (4,000 rpm) and the absorbance of the supernatant was read 
at 390 nm (ε = 22 mM−1).
Malonyldialdehyde (MDA) levels: MDA levels in the microsomal fraction were determined according to the 
method of Esterbauer and Zollner49. Samples were diluted in a solution with 1 mL acetic acid 20%, 1.5 mL of 
thiobarbituric acid (TBA) 0.8%, 0.2 mL of sodium dodecyl sulfate (SDS) 8%. The mixture was heated in a boiling 
water bath at 95 °C for 1 h. A calibration curve was carried out using 1,1,3,3-tetramethoxypropane dissolved in 
water and properly diluted. Absorbance was read at 535 nm. Results were expressed as moles of MDA h−1 mg 
protein−1.
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Micronuclei assay. Human fibroblasts (IMR90) were maintained in minimum essential medium (MEM) 
with Earle’s Salts and L-glutamine containing 10% fetal bovine serum (FBS), MEM vitamins and amino acids, and 
penicillin-streptomycin (all from Sigma Aldrich, St. Louis, MO, USA). Cells were seeded onto glass coverslips at 
a density of 10,000 cells for cm2 and treated with vitamin E (100 μM) and NCS 0.1 µM and 0.5 µM (from Sigma 
Aldrich, St. Louis, MO, USA). Since vitamin E was diluted in DMSO, same amounts of DMSO were applied in 
control samples. After pre-incubation with vitamin E for 48 h, the cells were rinsed twice and treated with NCS 
(0.1 μM and 0.5 μM) for 2 h, after two additional washes the cells were finally incubated for 24 h in MEM with or 
without DMSO. Cells were fixed with 4% paraformaldehyde, permeabilized in 0.2% Triton X100 in PBS, stained 
with DAPI (1 μL of DAPI in 5 mL of 0.1% PBS-BSA) and mounted with Vectashield Mounting Medium (Vector 
Laboratories, Burlingame, CA, USA) before analysis with an Olympus IX50 fluorescence microscope equipped 
with a Canon camera.
Micronuclei, defined as DAPI-positive bodies that were morphologically identical to but smaller than the 
nucleus, were scored counting at least 1,000 nuclei per slide.
Immunofluorescence determination of 53BP1 and γH2AX. On IMR90 human fibroblasts cultured 
as previously described in the micronucleus assay section and unsynchronized, DNA damage foci were scored 
following immunofluorescent staining performed as previously described33,50. Nuclei were scored as containing: 
γH2AX and 53BP1 foci (F): F ≤ 5; 5 < F ≤ 20; F > 20.
Cell transformation assay. The original stock of BALB/c 3T3 cells, clone A31-1-1, was obtained from the 
Health Science Research Resource Bank (Osaka, Japan). Cells were grown in minimum essential medium (MEM) 
supplemented with 10% fetal bovine serum (FBS, Gibco BRL) and maintained in a humidified incubator with an 
atmosphere of 5% CO2 in air at 37 °C. For the cell transformation assay (CTA), sub-confluent cells were seeded 
at a density of 3 × 104 cells/2 ml/60-mm plate, 10 replicates for each treatment. At 24 h after seeding, cells were 
treated with vitamin E. The stock solution of vitamin E (1 M in DMSO) was diluted 1:10 in DMSO and then in 
MEM, to obtain a 300 µM working solution. The final concentration of vitamin E (100 µM) was obtained by 1:3 
dilution of the 300 µM solution directly into cell culture plates. Untreated cells and DMSO-treated cells received 
1 ml of MEM or 0.1% DMSO solution, respectively. At 48 h after seeding, the treatment solutions were removed 
and replaced with medium containing benzo[a] pyrene (B[a]P, CAS number 50-32-8, purity 96%, Ultra Scientific 
Italia). The working solutions of B[a]P were prepared by 1:1,000 dilution of the DMSO stock solutions immedi-
ately before use. The final concentrations ranged from 1 µg/ml to 0.01 µg/ml. Positive controls were represented by 
cells treated with 4 µg/ml 3-methylcholanthrene (MCA, CAS number 56-49-5, purity 99%, Ultra Scientific Italia). 
The working solution was prepared by diluting MCA in DMSO at 4 mg/ml and then 1:1,000 in M10F. DMSO 
(CAS number 67-68-5), which was used as the solvent vehicle for all the chemicals, was administered to cell cul-
tures at a final concentration of 0.1%. At 96 h after seeding, the treatment solutions were removed and replaced 
with MEM. Cells were maintained in culture for 4 weeks with twice weekly medium changes, then fixed with 
methanol, stained with 10% aqueous Giemsa and scored for foci formation. The foci hallmarks for the inclusion 
were detailed reported previously35.
Statistical analysis. Data sets on RWPE-1 cells were analyzed using the two-tailed t-test. Data from in 
vivo experiments were analyzed using the ANOVA test with Sidak correction for multiple comparisons. Data 
from micronuclei assay and immunofluorescence determination of 53BP1 and γH2AX were analyzed using the 
unpaired t-test. Data from transformation assay were analyzed by the one tailed Mann–Whitney unpaired t-test. 
TF statistical significance was assessed by comparing the Poisson rates51. Unless otherwise indicated, data from 
each group were compared with relative control. *P < 0,05; **P < 0,01; ***P < 0,001.
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